GeoVax Labs, Inc. — Q3 2021 Form 10-Q
Business and reporting period: Clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. This unaudited report covers the quarter and nine months ended September 30, 2021; comparisons are with the same 2020 periods.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Grant and collaboration revenue | $30,414 | $415,458 | $220,539 | $1,572,037 |
| Research and development expense | $1,224,362 | $416,756 | $2,659,980 | $1,687,113 |
| General and administrative expense | $757,432 | $435,013 | $2,562,641 | $1,364,650 |
| Net loss | $1,950,503 | $570,648 | $4,827,314 | $1,621,546 |
| Net loss per common share | $0.31 | $0.73 | $0.80 | $2.85 |
At September 30, cash and cash equivalents were $18.1 million, working capital was $17.8 million, total assets were $18.3 million, and total liabilities were $335,650. The company had no notes payable outstanding after repaying its Georgia Research Alliance note and receiving forgiveness of its PPP loan. No product sales were reported; the filing does not present meaningful product gross margins.
For the first nine months, operating cash use was $4.5 million, investing cash use was $47,718, and financing provided $12.8 million. Cash increased by $8.2 million from year-end 2020. Financing included $9.4 million net proceeds from a public stock offering and $3.4 million from warrant exercises.
Material changes and notable items
- Revenue fell 93% for the quarter and 86% for the nine-month period, primarily reflecting the mix and timing of grants and collaborations. The company reported $244,888 of approved grant funds remaining through mid-2022.
- Operating expenses rose substantially: R&D increased 194% for the quarter and 58% year to date; G&A increased 74% and 88%, respectively. The company attributed the R&D increase partly to the Gedeptin in-license and COVID-19 vaccine work, and the G&A increase to higher franchise taxes and legal, accounting, patent, insurance, consulting, listing, investor-relations, and personnel costs.
- Q3 and nine-month R&D expense included $459,825 of upfront Gedeptin license-related expense, including $209,825 recorded for a warrant issued to PNP Therapeutics. The nine-month results also included a $172,056 gain on PPP loan extinguishment.
- Common shares outstanding increased to 6,381,541 at September 30 from 3,834,095 at December 31, 2020, reflecting the offering and warrant exercises, among other issuances.
Outlook, risks, and contingencies
Management expected existing cash to support anticipated requirements through mid-2022, but warned that this estimate depends on assumptions and that further capital will be needed. It expects operating losses and negative operating cash flows for the foreseeable future, with increased research, development, and licensing costs as programs advance. The company reported no product revenue and no assurance of profitability or additional financing.
On November 9, 2021, after quarter-end, GeoVax licensed exclusive worldwide rights to City of Hope’s COH04S1 COVID-19 vaccine program, then in Phase 2 trials. The agreement requires a $5 million upfront payment within 30 days, additional payments of $3 million and $2 million on the first and second anniversaries, plus potential milestones and royalties. This commitment postdates the September 30 balance sheet and may affect the previously stated cash-runway outlook.
Other disclosed commitments include approximately $607,000 of vendor and subcontractor purchase commitments expected to be due in 2021. The office and laboratory lease runs through December 2022 but may be terminated by either party with 90 days’ written notice. Management identified development, clinical-trial, manufacturing, regulatory, financing, and pandemic-related uncertainties. It reported no material change to previously disclosed risk factors, no legal proceedings, and effective disclosure controls.
Important facts for investors to verify
- How the $5 million City of Hope upfront fee and subsequent license payments affect liquidity and the mid-2022 runway estimate.
- Cash-burn trends and the timing and availability of additional financing, grants, or collaboration funding.
- Clinical progress and funding status for COH04S1, Gedeptin, and other vaccine programs, including trial delays noted for HIV studies.
- Potential dilution from outstanding warrants and options; 2,816,631 warrants and 602,000 options were outstanding at September 30, 2021.
- Whether grant funding and collaborations continue to support program costs as revenue remains low and operating expenses rise.